The present study was performed to investigate the influence of the intake of selective oestrogen receptor modulators on the urinary endogenous steroids profile. For this purpose the circadian variability of luteinizing hormone, follicle-stimulating hormone, testosterone, 5 alpha-androstan-3 alpha,17 beta-diol, 5 beta-androstan-3 alpha,17 beta-diol, epitestosterone, 4-androstenedione, androsterone and etiocholanolone were measured on eight subjects (four males and four females) by gas chromatography-mass spectrometry and chemiluminescent immunometric assay techniques before and after oral administration of multiple doses of either tamoxifen (80 mg for 2 days) or toremifene (120 mg for 2 days) or clomiphene (100 mg for 2 days). The individual baseline variability of the steroids studied was set up by collecting the urine samples every 3 h, for 3 days prior to the treatment: whereas the evaluation of the effects of the oral administration of multiple doses of selective oestrogen receptor modulators on the steroid urinary profile was assessed by collecting urine samples every three hours for at least five days from the first administration. The results of our measurements showed that, only in male subjects, the relative urinary concentrations of testosterone, epitestosterone and 4-androstenedione were significantly altered generally after the second day of drug administration. While no significant effects were recorded in both sexes on the luteinizing hormone, follicle-stimulating hormone, androsterone, etiocholanolone, 5 alpha-androstan-3 alpha,17 beta-diol and 5 beta-androstan-3 alpha,17 beta-diol urinary levels and on testosterone/epitestosterone, 5 alpha-androstan-3 alpha,17 beta-diol/5 beta-androstan-3 alpha,17 beta-diol and androsterone/etiocholanolone ratios. (C) 2011 Elsevier Inc. All rights reserved.

Relevance of the selective oestrogen receptor modulators tamoxifen, toremifene and clomiphene in doping field: Endogenous steroids urinary profile after multiple oral doses / Monica Mazzarino; Maria Cristina Bragano; Xavier De La Torre; Francesco Molaioni; BOTRE', Francesco. - In: STEROIDS. - ISSN 0039-128X. - STAMPA. - 76:(2011), pp. 1400-1406. [10.1016/j.steroids.2011.06.005]

Relevance of the selective oestrogen receptor modulators tamoxifen, toremifene and clomiphene in doping field: Endogenous steroids urinary profile after multiple oral doses

BOTRE', Francesco
2011

Abstract

The present study was performed to investigate the influence of the intake of selective oestrogen receptor modulators on the urinary endogenous steroids profile. For this purpose the circadian variability of luteinizing hormone, follicle-stimulating hormone, testosterone, 5 alpha-androstan-3 alpha,17 beta-diol, 5 beta-androstan-3 alpha,17 beta-diol, epitestosterone, 4-androstenedione, androsterone and etiocholanolone were measured on eight subjects (four males and four females) by gas chromatography-mass spectrometry and chemiluminescent immunometric assay techniques before and after oral administration of multiple doses of either tamoxifen (80 mg for 2 days) or toremifene (120 mg for 2 days) or clomiphene (100 mg for 2 days). The individual baseline variability of the steroids studied was set up by collecting the urine samples every 3 h, for 3 days prior to the treatment: whereas the evaluation of the effects of the oral administration of multiple doses of selective oestrogen receptor modulators on the steroid urinary profile was assessed by collecting urine samples every three hours for at least five days from the first administration. The results of our measurements showed that, only in male subjects, the relative urinary concentrations of testosterone, epitestosterone and 4-androstenedione were significantly altered generally after the second day of drug administration. While no significant effects were recorded in both sexes on the luteinizing hormone, follicle-stimulating hormone, androsterone, etiocholanolone, 5 alpha-androstan-3 alpha,17 beta-diol and 5 beta-androstan-3 alpha,17 beta-diol urinary levels and on testosterone/epitestosterone, 5 alpha-androstan-3 alpha,17 beta-diol/5 beta-androstan-3 alpha,17 beta-diol and androsterone/etiocholanolone ratios. (C) 2011 Elsevier Inc. All rights reserved.
2011
76
1400
1406
Monica Mazzarino; Maria Cristina Bragano; Xavier De La Torre; Francesco Molaioni; BOTRE', Francesco
File in questo prodotto:
File Dimensione Formato  
Steroids 76 (2011) 1400–1406.pdf

Accesso chiuso

Licenza: Tutti i diritti riservati
Dimensione 485.55 kB
Formato Adobe PDF
485.55 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1418880
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 29
social impact